We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current IPHYF market cap is 177.89M. The company's latest EPS is EUR -0.0936 and P/E is -26.82.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 85.81M | 71.32M | 26.5M | 57.89M | 61.64M |
| Operating Income | -27.05M | -62.08M | -54.98M | -57.53M | -12.67M |
| Net Income | -20.76M | -63.98M | -52.81M | -58.1M | -7.57M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 401.36M | 307.42M | 267.5M | 207.86M | 184.19M |
| Total Liabilities | 183.95M | 151.45M | 160.06M | 153.71M | 132.29M |
| Total Equity | 217.42M | 155.98M | 107.44M | 54.15M | 51.9M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 34.92M | -51.77M | -58.46M | -19.15M | -32.56M |
| Investing | -62.12M | -13.37M | -917k | 1.88M | 20.63M |
| Financing | 77.77M | -1.18M | 26.82M | -1.83M | -1.97M |
| Market Cap | 177.89M |
| Price to Earnings Ratio | -26.82 |
| Price to Sales Ratio | 3.29 |
| Price to Cash Ratio | 2.87 |
| Price to Book Ratio | 3.91 |
| Dividend Yield | - |
| Shares Outstanding | 80.86M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Innate Pharma (PK) |
| Address |
117 avenue de luminy marseille, bouches-du-rhone 13009 |
| Website | https://www.innate-pharma.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
